In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wright Medical launches injectable bone graft worldwide:

This article was originally published in Clinica

Executive Summary

Wright Medical has launched worldwide its Pro-dense injectable regenerative graft, a bone graft substitute. While the product received US FDA approval in February 2006, it was released in a controlled fashion to select institutions to confirm human effectiveness over a 17-month period, said the Arlington, Tennessee firm. "Extra time and resources were invested in order to generate strong clinical experience prior to our full-scale commercial release," said John Treace, VP of marketing for Wright's biologics division. Studies have shown that when bone voids are treated with Pro-dense, new bone tissue formed at a faster rate than with autograft - widely considered to be the gold standard, claimed the firm.

You may also be interested in...



Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

Aurobindo Upbeat On Outlook, Transfers Biologics Biz

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Some Annex XVI Products Likely To Be Delayed, Updated European Commission Rolling Plan Suggests

The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.

Topics

UsernamePublicRestriction

Register

LL015829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel